D.H.E. 45
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Apr 1946
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
D.H.E. 45 is a dihydroergotamine mesylate injectable approved in 1946 for acute migraine and cluster headache management. The drug is a vasoconstrictor and ergot alkaloid derivative administered via intramuscular, intravenous, or subcutaneous injection. It works by narrowing blood vessels around the brain and reducing substances in the body that cause headache, pain, sensitivity to light and sound, and other migraine symptoms.
LOE Approaching
As a legacy product approaching LOE, D.H.E. 45 operates with a small commercial footprint and minimal team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
D.H.E. 45 represents a niche legacy career opportunity with limited upside; roles are primarily focused on maintaining existing patient access, managing relationships with neurology specialists, and regulatory compliance rather than driving growth or innovation. Career mobility is constrained, as the product offers minimal visibility for advancement to high-growth or strategic initiatives within a modern pharmaceutical organization.
Field Sales Representative (specialty)
Worked on D.H.E. 45 at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.